Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q3 FY2017-18 Earnings Presentation
8 slides from Aurobindo Pharma's earnings presentation, Feb 7, 2018
Slide 1: Q3 FY17-18 Earnings Presentation
Q3 FY17-18 EARNINGS PRESENTATION 7th February 2018
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Consolidated Financial & Business Highlights – Q3FY18
Consolidated Financial & Business Highlights – Q3FY18 Key Financial Highlights • Revenue from operations at INR 4,336.1 crore, witnessed a growth of 11.0% YoY • EBIDTA before forex and other income at INR 1,025.6 crore, up by 14.6% YoY; EBITDA margin at 23.7% in Q3FY18 as compared to 22.9% in Q3FY17
Slide 4: US Filings Snapshot
US Filings Snapshot Addressable Cumulative ANDA Filings and Approvals Therapy ANDAs Market Size (US$ Bn) Anti Diabetic 13 4.8 ARV** 41 7.4 CNS 87 25.1 Controlled Substances 16 1.8 CVS 73 24.8 Gastroenterological 30 4.3 Ophthalmics 11 0.5 Others 139 14.6 Penem 4 0.5 Respiratory 11 0.7 Oncology & Horm
Slide 5: Consolidated Financial Performance – Q3FY18 YoY
Consolidated Financial Performance – Q3FY18 YoY Q3 Q3 % Value INR Cr Revenue from Operations - Breakup FY18 FY17 Chg Value in INR Cr Q3FY18 Q3FY17 % Chg Formulations 3,570.2 3,130.2 14.1 USA 1,909.6 1,745.1 9.4 API 765.7 775.9 -1.3 EU 1,171.6 855.4 37.0 Formulations % of sales 82.3% 80.1% Growth mar
Slide 6: Consolidated Financial Performance – 9MFY18 YoY
Consolidated Financial Performance – 9MFY18 YoY 9M 9M % Revenue from operations - Breakup Value INR Cr FY18 FY17 Chg Value in INR Cr 9MFY18 9MFY17 % Chg Formulations 10,284.6 9,166.0 12.2 USA 5,703.3 5,184.1 10.0 API 2,162.6 2,279.2 -5.1 EU 3,202.7 2,499.9 28.1 Growth markets 687.5 558.5 23.1 Formul
Slide 7: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Sep-17 Dec-17 Closing Rate1 US$ = 66.255 64.85 65.285 63.875 INR Fx Loan restated in 4,956.7 3,121.5 4,930.6 4,608.8 690 748 481 755 722 INR Rupee Loan 46.9 244.8 70.1 92.9 Sales Tax Deferment 41.9 0.0 0.0 0.0 Gross Debt 5,045.6 3,366.3 5
Slide 8: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register
Aurobindo Pharma — Q3 FY2017-18 Earnings Presentation on 6ix